Data Strategist, AI/ML Scientist, Innovator, Digital Health Enthusiast | Big data for better health | Roche, IQVIA, Merck, MIT
Basel, Switzerland
Joined November 2013
- Tweets813
- Following586
- Followers150
- Likes560
Ivan John Clement retweeted
A 19-year-old Japanese student built a trading bot with Claude Code in 2 days.
Used his iPad as a second monitor.
First night: $6,732 profit.
Starting capital: $68.
Total profit so far: $750,000.
Here's how it works:
The bot scans over 50 markets simultaneously.
Syncs live BTC data from Binance every second.
Spots price errors before humans even notice.
The edge is pure speed + pattern recognition.
While traders stare at charts trying to predict the next move, his bot is already executing on mispricing across dozens of markets.
No guessing.
No emotions.
No hesitation.
Just Claude Code logic finding gaps that close in seconds.
He built the entire system in 48 hours:
→ Claude Code handles the trading logic
→ Binance API feeds real-time BTC data
→ iPad displays multi-market monitoring
→ Executes trades when arbitrage windows open
The system runs 24/7.
Every price dislocation = profit opportunity.
Most people are still trading manually, refreshing charts, second-guessing entries.
Meanwhile this 19-year-old engineering student turned $68 into $750K by letting Claude Code do what humans can't: process 50 markets instantly and execute without fear.
Why are people still trading manually?
💡 I'm giving away the exact Claude Code setup for free.
24 hours only.
To get it:
1️⃣ Comment "Fable"
2️⃣ Like and Repost
3️⃣ Follow @Faazsh
I'll DM you the complete setup.
An interesting and much-needed development - such a "mechanism-driven" framework for MS is reminiscent of how oncology treatment decisions are more and more based on cancer genomic profiles. This, I believe, is but a stepping stone towards a future with m…lnkd.in/ePxfMM9t
I am blessed to have shared these past 3 days of energizing and insightful #medical and #realworldevidence discussions at the #ectrims2022 #medicalcongress with my 3-month old son. Reading #neurology to him is currently the best way to make him fall aslee…lnkd.in/exKgcv5A
Ivan John Clement retweeted
#AI & #Data - How to Make the Marriage Work
Phase #2: From Engagement to Marriage 💍➡️🗓️🧝🏻♀️🎊🎉❤️
In the spotlight: AI-driven renewed strategies
#CognitiveVirtual - 6 May - Agenda, Speakers, Registration:
➡️ bit.ly/3gDyKpW ⬅️
cc @Roche @davidmeza1
Indeed - when there’s enough “pressure”, we can find ways to shorten the whole drug/vaccine dev process without sacrificing on quality!
Ivan John Clement retweeted
Are we making meaningful progress on machine learning for EHR data?
New preprint with @DavidRBellamy and Leo Celi tries to answer this question through the lens of benchmarks and the answer is, unfortunately, "probably not"
Paper: arxiv.org/abs/2010.01149
Some highlights 👇
GET€ 20,00! #AliExpressbonus #BonusBuddies
Your bonus is waiting to be activated.
a.aliexpress.com/_mME6SsT
Ivan John Clement retweeted
I'm excited to announce... we're unveiling a landmark collaboration, 𝑇ℎ𝑒 𝑃𝑙𝑎𝑦𝑏𝑜𝑜𝑘, the essential how-to guide to develop and deploy digital clinical measures across clinical care, research, and public health.
Launching tomorrow! Sneak peek: playbook.dimesociety.org
Ivan John Clement retweeted
Take the competitive advantage of applying machine learning to small data sets. Paired with deep human knowledge, could be a game changer!
hbr.org/amp/2020/02/small-da…
#datascience #machinelearning #ArtificialIntelligence #data #ai #bigdata #deeplearning #analytics #statistics
Good to see the developments in the #digital #endpoints space for #pharma! Give it a few more years and we won’t be able to imagine a world where clinical trials won’t have such!
30+ pharma companies have submitted a digital endpoint to regulators to support a primary, secondary, or label claim.
This tech isn't "exploratory" anymore. It's core to drug development.
Welcome to the world of decentralized clinical trials. 🚀
dimesociety.org/index.php/kn…
Ivan John Clement retweeted
Humankind has never had a more urgent task than creating broad immunity for coronavirus. It’s going to require a global cooperative effort like the world has never seen. But I know we’ll get it done. There’s simply no alternative. gatesnot.es/3d06cC2
“In broad terms, an agile organization is one that combines a stable backbone of core processes and capabilities with a high degree of flexibility for rapid response to change.”
And data+analytics can help in the agile transformat…lnkd.in/fp-_7cF lnkd.in/f-p4K_h
“Alphabet’s Google will bring its artificial-intelligence and cloud-computing capabilities to a new partnership with pharma giant Sanofi.
The project is aimed at accelerating the discovery of new medicines, increasing the understa…lnkd.in/fSe3GZM lnkd.in/faiCPFa
“How do [different clinical] specialties work together with primary care around the A1C and not only slow the progression of diabetes, but also the complications and comorbidities that are exacerbated by their diabetes? ...that is…lnkd.in/fWzZ_fv lnkd.in/f7R_sTS
Atomwise incorporates protein structure data in its analysis to not only identify promising compounds from known libraries, but also to make predictions for virtually synthesized novel molecules that have never physically existed.…lnkd.in/fM2w-XT lnkd.in/fQVMmwN
Sounds a lot like OHDSI (i.e. in the observational/real-world evidence space), but for pharma drug discovery!
“MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery) project...aims, for the first time, to use machine…lnkd.in/fwiXbbF lnkd.in/fhTKyGR
Cool study with deep multi-omics data enabling the investigation of early molecular signs of diabetes progression at an individual level! lnkd.in/frE_-nW
Wow exciting stuff for an MNC pharma to open a global HQ in China!
“In his opening speech, Group President Michael Goettler stressed the significance of this historic moment...’Basing our global headquarters in China will enable u…lnkd.in/fS3wbQM lnkd.in/fbSjdJV
When asked to identify the greatest challenge facing their #translationalmedicine (TM) groups, 76% of respondents pointed to the difficulty in defining clear metrics to measure long-term success, given the additive impact of TM activities on the overall R…lnkd.in/fHqxvr8